Last update April 25, 2022

νιζατιδίνη

Compatible

Safe product and/or breastfeeding is the best option.

Nizatidine is a histamine H2 antagonist with actions and uses similar to those of cimetidine. It inhibits gastric acid secretion and pepsin production. It is used in peptic ulcer and gastroesophageal reflux. Oral or parenteral administration once or twice daily.

It is excreted in breast milk in a clinically insignificant amount and no problems have been observed in the infant whose mother had taken it. (Obermeyer 1990)

Several medical societies, experts and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding. (Hale, Briggs 2015, Rowe 2013, Mahadevan 2006, Richter 2005, Nice 2000, Lee 1993)

Famotidine and Nizatidine are excreted into milk but in less proportion than Cimetidine or Ranitidine, which have been proposed as alternative to during lactation. (Rowe 2013, Nice 2000, Hagemann 1998, Lee 1993)

Alternatives

  • Famotidine (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

νιζατιδίνη belongs to this group or family:

Tradenames

Main tradenames from several countries containing νιζατιδίνη in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 70 - 94 %
Molecular weight 331 daltons
Protein Binding 35 %
VD 0.8 - 1.5 l/Kg
Tmax 3 hours
1 - 2 hours
Theoretical Dose 0.08 mg/Kg/d
Relative Dose 1.59 %

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  2. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  3. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)
  4. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005 Nov 1;22(9):749-57. Review. Abstract Full text (in our servers)
  5. Nice FJ, Snyder JL, Kotansky BC. Breastfeeding and over-the-counter medications. J Hum Lact. 2000 Nov;16(4):319-31. Review. Erratum in: J Hum Lact 2001 Feb;17(1):90. Abstract
  6. Hagemann TM. Gastrointestinal medications and breastfeeding. J Hum Lact. 1998 Sep;14(3):259-62. Review. Abstract
  7. Lee JJ, Rubin AP. Breast feeding and anaesthesia. Anaesthesia. 1993 Jul;48(7):616-25. Review. Abstract Full text (link to original source) Full text (in our servers)
  8. Obermeyer BD, Bergstrom RF, Callaghan JT, Knadler MP, Golichowski A, Rubin A. Secretion of nizatidine into human breast milk after single and multiple doses. Clin Pharmacol Ther. 1990 Jun;47(6):724-30. Abstract

Total visits

849

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM